BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 25032534)

  • 1. Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.
    Price RL; Chiocca EA
    Neurosurgery; 2014 Aug; 61 Suppl 1(0 1):74-83. PubMed ID: 25032534
    [No Abstract]   [Full Text] [Related]  

  • 2. Viruses in the treatment of malignant glioma.
    Everson RG; Gromeier M; Sampson JH
    Expert Rev Neurother; 2007 Apr; 7(4):321-4. PubMed ID: 17425484
    [No Abstract]   [Full Text] [Related]  

  • 3. [Oncolytic viruses for therapy of malignant glioma].
    Sosnovtceva AO; Grinenko NF; Lipatova AV; Chumakov PM; Chekhonin VP
    Biomed Khim; 2016 May; 62(4):376-90. PubMed ID: 27562991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic HSV-1 for the treatment of brain tumours.
    Markert JM; Parker JN; Buchsbaum DJ; Grizzle WE; Gillespie GY; Whitley RJ
    Herpes; 2006 Nov; 13(3):66-71. PubMed ID: 17147910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for Brain Tumors.
    Hoang-Minh LB; Mitchell DA
    Curr Treat Options Oncol; 2018 Oct; 19(11):60. PubMed ID: 30311004
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Virotherapy in Glioma Tumors.
    Rius-Rocabert S; García-Romero N; García A; Ayuso-Sacido A; Nistal-Villan E
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic Virotherapy for the Treatment of Malignant Glioma.
    Foreman PM; Friedman GK; Cassady KA; Markert JM
    Neurotherapeutics; 2017 Apr; 14(2):333-344. PubMed ID: 28265902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene Therapy and Virotherapy of Gliomas.
    Kim JW; Chang AL; Kane JR; Young JS; Qiao J; Lesniak MS
    Prog Neurol Surg; 2018; 32():112-123. PubMed ID: 29990979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Oncolytic viruses in the therapy of gliomas].
    Gubanova NV; Gaĭtan AS; Razumov IA; Mordvinov VA; Krivoshapkin AL; Netesov SV; Chumakov PM
    Mol Biol (Mosk); 2012; 46(6):874-86. PubMed ID: 23350233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy.
    Spencer DA; Young JS; Kanojia D; Kim JW; Polster SP; Murphy JP; Lesniak MS
    Ther Deliv; 2015; 6(4):453-68. PubMed ID: 25996044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.
    Kaliberova LN; Krendelchtchikova V; Harmon DK; Stockard CR; Petersen AS; Markert JM; Gillespie GY; Grizzle WE; Buchsbaum DJ; Kaliberov SA
    Cancer Gene Ther; 2009 Oct; 16(10):794-805. PubMed ID: 19363468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Local Therapy for Management of Intracranial High-Grade Gliomas.
    Paldor I; Chaichana KL; Brem H; Tyler BM
    Prog Neurol Surg; 2018; 32():159-171. PubMed ID: 29990982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic study of neural stem cell-based cell carrier for oncolytic virotherapy: targeted delivery of the therapeutic payload in an orthotopic brain tumor model.
    Thaci B; Ahmed AU; Ulasov IV; Tobias AL; Han Y; Aboody KS; Lesniak MS
    Cancer Gene Ther; 2012 Jun; 19(6):431-42. PubMed ID: 22555507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil.
    Zemp FJ; Corredor JC; Lun X; Muruve DA; Forsyth PA
    Cytokine Growth Factor Rev; 2010; 21(2-3):103-17. PubMed ID: 20483653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo.
    Tyler MA; Ulasov IV; Sonabend AM; Nandi S; Han Y; Marler S; Roth J; Lesniak MS
    Gene Ther; 2009 Feb; 16(2):262-78. PubMed ID: 19078993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models.
    Geletneky K; Kiprianova I; Ayache A; Koch R; Herrero Y Calle M; Deleu L; Sommer C; Thomas N; Rommelaere J; Schlehofer JR
    Neuro Oncol; 2010 Aug; 12(8):804-14. PubMed ID: 20299703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative study of neural and mesenchymal stem cell-based carriers for oncolytic adenovirus in a model of malignant glioma.
    Ahmed AU; Tyler MA; Thaci B; Alexiades NG; Han Y; Ulasov IV; Lesniak MS
    Mol Pharm; 2011 Oct; 8(5):1559-72. PubMed ID: 21718006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The integrin inhibitor cilengitide enhances the anti-glioma efficacy of vasculostatin-expressing oncolytic virus.
    Fujii K; Kurozumi K; Ichikawa T; Onishi M; Shimazu Y; Ishida J; Chiocca EA; Kaur B; Date I
    Cancer Gene Ther; 2013 Aug; 20(8):437-44. PubMed ID: 23827879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mesenchymal stromal cells for the delivery of oncolytic viruses in gliomas.
    Parker Kerrigan BC; Shimizu Y; Andreeff M; Lang FF
    Cytotherapy; 2017 Apr; 19(4):445-457. PubMed ID: 28233640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active immunotherapy: oncolytic virus therapy using HSV-1.
    Todo T
    Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.